The stock of Allogene Therapeutics Inc. (NASDAQ:ALLO) increased by $0.02 on Wednesday to $3.93, up 0.51 percent. The last five days have seen an average of 1,818,146 shares of common stock traded. 7 times new highs were reached in the current year, with a fall of -$2.37. The average number of shares traded over the last 20 days was 1,653,491, while the average volume over the last 50 days totaled 1,887,307.
ALLO stock appreciated 0.77% since last month. On 08/21/23, the company’s shares reached a one-month low of $3.70. The stock touched a high of $13.64 on 01/27/23, after rallying from a low of $3.70 in 52 weeks. The price of ALLO stock has declined by -37.52% or -$2.37 this year, reaching a new high 7 times. Still, the stock price is down -71.19% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ALLO stock investors should be aware that Allogene Therapeutics Inc. (ALLO) stock had its last reported insider trading activity 44 days ago on Aug 07. On Aug 07, Director Mayo Stephen sold 10,000 shares at $4.29 each. This transaction resulted in the insider making $42,855. On Feb 13, Bhavnagri Veer sold 3,000 shares at a price of US$6.85. After the transaction, the insider now owns 577,677 shares. General Counsel Bhavnagri Veer had earlier sold 3,000 shares on Jan 17 for $7.04 a share. The transaction was completed for $21,120.
Valuation Metrics
Beta for the stock is 0.76. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 3344.63, the price-to-book (PB) ratio of 0.93.
Financial Health
For the three months ended June 29, Allogene Therapeutics Inc.’s quick ratio was 9.20, while its current ratio was 9.20, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $335.69 million and revenue of $0.24 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ALLO’s return on assets (ROA) during the last 12 months has been -44.00%. In the meantime, the return on equity (ROE) for the last 12 months was -54.10%.
Earnings Surprise
According to Allogene Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $40000.0, while revenues fell by -125.0% to $50000.0. It was predicted that Allogene Therapeutics Inc.’s quarterly earnings would be -$0.53, but it ended up being -$0.59, beating the consensus by 10.20%. EBITDA was -$77.95 million for the quarter. At the end of Allogene Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 148.06 million, while its total debt was $98.2 million. Equity owned by shareholders amounts to $167.63 million.
Technical Picture
Here’s a quick look at Allogene Therapeutics Inc.’s (ALLO) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 44.69%, suggesting the stock is Neutral, with a 45.07% historical volatility rate.
The stochastic %K and %D were 27.29% and 28.08% respectively, while the average true range (ATR) was 0.18. Based on the 14-day stochastic reading of 28.00%, the RSI (14) reading is 43.58%. On the 9-day MACD Oscillator, the stock is at -0.07, and the 14-day reading is at -0.08.
Analyst Ratings
Analysts have assigned Allogene Therapeutics Inc. (ALLO) an Overweight rating. ALLO is a stock that is recommended for selling by 0 brokerage firms, while 3 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 1 rate it overweight and 14 others recommend it as a buy.
What is ALLO’s price target for the next 12 months?
The current consensus forecast for the stock is between $5.00 and $35.00, with a median target price of $15.00. In analyzing these forecasts, the average price target given by analysts for Allogene Therapeutics Inc. (ALLO) is $16.13.
